TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer

Oncogenic KRAS mutations are encountered in more than 90% of pancreatic ductal adenocarcinomas. MEK inhibition has failed to procure any clinical benefits in mutant RAS-driven cancers including pancreatic ductal adenocarcinoma (PDAC). To identify potential resistance mechanisms underlying MEK inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ben, Dierichs, Laura, Gu, Jiang-Ning, Trajkovic-Arsic, Marija, Axel Hilger, Ralf, Savvatakis, Konstantinos, Vega-Rubin-de-Celis, Silvia, Liffers, Sven-Thorsten, Peña-Llopis, Samuel, Behrens, Diana, Hahn, Stephan, Siveke, Jens T., Lueong, Smiths S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066197/
https://www.ncbi.nlm.nih.gov/pubmed/32194992
http://dx.doi.org/10.1038/s41420-020-0246-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066197/
https://www.ncbi.nlm.nih.gov/pubmed/32194992
http://dx.doi.org/10.1038/s41420-020-0246-7

Ejemplares similares